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Abstract
Introduction: Timeliness of laboratory results is crucial to patient care and outcome. Monitoring turnaround times (TAT), especially for emergency 
tests, is important to measure the effectiveness and efficiency of laboratory services. Laboratory-based clinical audits reveal opportunities for im-
proving quality. Our aim was to identify the most critical steps causing a high TAT for cerebrospinal fluid (CSF) chemistry analysis in our laboratory.
Materials and methods: A 6-month retrospective audit was performed. The duration of each operational phase across the laboratory work flow 
was examined. A process-mapping audit trail of 60 randomly selected requests with a high TAT was conducted and reasons for high TAT were tested 
for significance. 
Results: A total of 1505 CSF chemistry requests were analysed. Transport of samples to the laboratory was primarily responsible for the high avera-
ge TAT (median TAT = 170 minutes). Labelling accounted for most delays within the laboratory (median TAT = 71 minutes) with most delays occu-
rring after regular work hours (P < 0.05). CSF chemistry requests without the appropriate number of CSF sample tubes were significantly associated 
with delays in movement of samples from the labelling area to the technologist’s work station (caused by a preference for microbiological testing 
prior to CSF chemistry).
Conclusion: A laboratory-based clinical audit identified sample transportation, work shift periods and use of inappropriate CSF sample tubes as 
drivers of high TAT for CSF chemistry in our laboratory. The results of this audit will be used to change pre-analytical practices in our laboratory with 
the aim of improving TAT and customer satisfaction.
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Introduction
Laboratory-based clinical audit is an important 
process in obtaining feedback for continual im-
provement. It involves measuring laboratory per-
formance using selected quality indicators and de-
fined benchmarks (1,2). Audits in the laboratory 
are used to determine the root cause of non-con-
formities and assess the effectiveness of changes 
made.
Timeliness of laboratory results as a quality indica-
tor assesses the effectiveness and efficiency of the 
total testing process and is expressed as turna-
round time (TAT) for laboratory tests (3-5). The im-
pact of TAT on the hospital length of stay is well 
documented (6,7). It is also crucial to clinicians’ and 
patients’ satisfaction as highlighted in College of 
American Pathologists (CAP) Q-probes surveys 
(8,9). 
An improvement of TAT may require increased 
manpower and use of sophisticated equipment 
with greater throughput and this is often not prac-
tical, especially in low income settings (10-12). Lean 
management of TAT, by redesigning the existing 
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work flow to utilize time efficiently, is often neces-
sary for addressing challenges of high TAT. Under-
standing the root causes of high TAT using evi-
dence-based methods is therefore imperative for 
planning improvements. Consequently, regulatory 
and accrediting bodies advise clinical laboratories 
to target TAT in their continual improvement pro-
cess (13-15).
The implications of untimely laboratory results are 
perhaps better observed with emergency tests 
such as potassium, cardiac troponins and cerebro-
spinal fluid (CSF) chemistry. Delayed CSF results 
may result in grave consequences, especially in 
the setting of acute neurological diseases. Addi-
tionally, concerns about the stability of CSF ana-
lytes further underscore the need for rapid analy-
sis (16-18). Sample transport and other pre-analyti-
cal processes are known to affect TAT (2,19). The 
origin of the sample, for example inpatient versus 
outpatient, may also influence the TAT (20).
CSF chemistry presents a unique challenge for im-
provement of TAT, as it is one of the few panel tests 
ordered as an emergency request. CSF glucose, 
protein, chloride and microbiology are most often 
requested to diagnose suspected neurological in-
fections (21,22). The complete set of CSF results is 
usually required prior to reporting for sensible in-
terpretation and this may affect the TAT.  Samples 
are often shared between different sections of the 
laboratory such as microbiology and chemistry, 
leading to increased TAT.
Recent increases in our laboratory’s workload have 
had an expected adverse impact on TAT, including 
that of CSF chemistry requests. By means of a sys-
tematic audit, our goal was to use data spanning 
six months to identify the most important steps 
that cause high TAT for CSF chemistry analysis in 
our laboratory and investigate the factors respon-
sible. The results of this study will be used as a ba-
sis for improving TAT.
Materials and Methods
Study design
This retrospective audit was conducted on re-
quests for a CSF chemistry panel during a 6-month 
period from November 1st 2014 to April 30th 2015 
at the chemical pathology laboratory of Tygerberg 
Hospital, a tertiary referral teaching hospital in 
Cape Town, South Africa. The laboratory provides 
diagnostic pathology services to the teaching hos-
pital as well as regional hospitals and clinics and 
processes an average of 90,000 tests a month. 
The laboratory offers CSF protein, glucose and 
chloride analysis routinely as a panel. Other bio-
chemical tests such as lactate or adenosine deami-
nase are performed at special request. Requests 
for CSF chemistry and microbiology are often ac-
companied by the following CSF samples: one flu-
oride tube (glucose), one plain tube (protein and 
chloride) and another plain tube (microbiology). 
Occasionally, only one plain tube accompanies the 
request in which case microbiological analysis is 
given preference (due to potential contamination), 
after which the sample is retrieved for CSF protein 
and chloride analysis. These were recorded as 
non-conformities and data from these specimens 
were included in this study. 
CSF samples from within the hospital are trans-
ported to the laboratory central reception by the 
pneumatic tube system or are brought directly by 
hospital porters, physicians or patients’ relatives. 
Samples from regional hospitals and clinics are 
brought by special couriers. Work hours in labora-
tory reception are divided into three shifts: (i) reg-
ular shift (8 am to 4:30 pm), (ii) evening shift (4:30 
pm to 8 pm), and (iii) night shift (8 pm to 8 am).
Methods
Samples go through the processes of sorting, reg-
istration and labelling followed by immediate 
transport to the laboratory for analysis. The result 
of analysis is available for the clinicians after re-
view and authorization through the laboratory in-
formation system (LIS). The laboratory aims to fast-
track all STAT samples (including CSF samples) and 
to release the results within two hours. Emergency 
samples are marked as “STAT” and given prefer-
ence through all the phases of the testing cycle.
The LIS, DISA*LAB® (Laboratory System Technolo-
gies (Pty) Ltd, Cape Town, South Africa) captures 
information at relevant time points determined by 
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the operational workflow of the laboratory. The in-
formation extracted from the LIS was used to com-
pute the TAT to reflect the four operational peri-
ods, described in Table 1.
Requests, especially from external hospitals and 
those with missing entries or errors in the date or 
time, were excluded. Missing entries or errors oc-
curred whenever the laboratory staff at any opera-
tional point failed to register the appropriate sam-
ple details on the LIS. The total TAT refers to the 
time from collection of sample to the time of au-
thorization in the laboratory, whereas the within-
laboratory TAT refers to the time from receipt at 
laboratory reception to authorization of final re-
sult. The TATs of CSF chemistry (a STAT test) and 
plasma glucose (a routine test) were compared to 
determine if the measures put in place to fast track 
STAT samples in our laboratory were successful. 
Routine plasma glucose was used in this study 
since glucose is also a component of CSF panel. 
The agreed TAT for routine glucose in our labora-
tory is 120 minutes.
A focused group discussion (FGD), involving tech-
nologists and the laboratory manager, was used to 
identify potential reasons for the high TAT. Each 
participant was asked to give their views as to the 
cause of the high TAT and the three most common 
reasons were noted.  Sixty cases with above medi-
an TAT for the identified operational period were 
randomly selected. Thereafter, an audit trail was 
conducted on the LIS to closely examine the se-
lected cases by breaking down the TAT of the iden-
tified period into smaller operational phases. 
The operational period with the highest TAT (“sam-
ple processing”) consisted of three sub-phases 
namely:
(i)  Labelling (sample registration time to the time 
the label was printed)
(ii)  Transport to work area (time the label was 
printed to time of sample entry at worksta-
tion) 
(iii) Actual analysis (time of sample entry at work-
station to time result was authorized by tech-
nologist). 
The time of entry at work station was missing for 
two samples, affecting calculation of TAT for 
“transport to work area” and “analysis” phases so 
these were excluded in the test for significance for 
the possible reasons for high TAT. 
The study was approved by the Ethics Committee 
of the University of Stellenbosch (N15/05/039) and 
carried out according to the Declaration of Helsin-
ki. A waiver of consent was obtained as the study 
was retrospective and no patient results were 
used. Patient confidentiality was maintained at all 
times.
Statistical analysis
Data from DISA*LAB was exported to Microscoft 
Excel® 2013, version 15.0. Thereafter, analysis was 
done using Statistical Package for Social Sciences 
(SPSS® version 15.0. SPSS inc Chicago, USA). Assess-
ment of normality of data was done using the Sha-
piro-Wilk test at P < 0.05 significance level. TAT was 
expressed as median with interquartile range and 
90% completion time (TAT within which 90% of 
tests are completed) (9,19). The relationship be-
tween high TAT and the suggested responsible 
factors was tested for significance using Fisher’s 







































LIS – laboratory information system.
Table 1. Description of operational periods for CSF
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Results
Within the period under review a total of 2093 CSF 
requests were received. After excluding 588 re-
quests with missing entries or errors (involving 
time and date records), 1505 requests were ana-
lysed. The median total and within-laboratory TATs 
were 345 minutes and 147 minutes, respectively. 
As a percentage of the total and within-laboratory 
TAT, sample transportation accounted for most de-
lays with a median of 53.4% of the total TAT, whilst 
the period of sample processing accounted for a 
median of 65.5% of the within-laboratory TAT. The 
distribution of the TAT is summarized in Table 2.
The median duration of each process across the 
operational workflow for CSF chemistry was com-
pared to that of plasma glucose (Figure 1). Al-
though CSF chemistry had higher median trans-
portation and total TAT, registration and within-
laboratory TAT was lower compared to plasma glu-
cose. The median TAT for sample processing peri-
od however was almost identical. 
An audit trail of 60 randomly selected cases with 
above median sample processing TAT showed that 
labelling had the highest TAT with a median of 71 
minutes whilst transport to work area had the low-
est duration with a median of 10 minutes (Table 3).
Sample processing at non-regular work hours (af-
fecting labelling), sample sharing for chemistry 
and microbiological testing (affecting transport of 
sample to work station) and repeat testing for 
specimens with critical values (affecting the ana-
lytical phase) were the most common reasons giv-
en for the high sample processing TAT as obtained 
Transport Registration Processing Reporting Within laboratory TAT Total TAT
Median (minutes) 170 37 86 4 147 345
Median % of total TAT 53 11 28 1 47 –
Median % of within-laboratory TAT – 27 66 3 – –
Interquartile range (minutes) 108–277 20–67 62–126 2–11 103–214 248–484
90% completion time (minutes) 421 113 188 30 305 666
TAT – turnaround time.









(minutes) 71 10 39
Interquartile 
range (minutes) 46–111 6–26 24–65
90% completion 
time (minutes) 174 86 158
*Two samples had no record of receipt time at work station 
and were excluded from this analysis
Table 3. Summary of the distribution of TAT across the “sample 
processing” phases (for sixty requests with the highest TAT)
Figure 1. Median TAT across phases of workflow for CSF chem-
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cess but not for “movement to work station” or 
“analysis” phases. Compared to the regular work-
ing shift, a higher proportion of CSF samples la-
belled during the evening and night shift were 
likely to be in the upper quartile for TAT of this 
work phase (Table 3). Also, all cases of shared CSF 
sample were in the upper quartile of TAT for the 
phase of “transport to work station” compared to 
10 (10 / 48) to non-shared sample. Repeat testing 
was not significantly associated with the upper 
quartile TAT for analysis phase (Table 4).
Discussion
Our audit showed that the median within-laborato-
ry TAT in our laboratory for CSF chemistry (147 min) 
and routine glucose (170 min) exceeded our target 
TAT (120 min). This is contrary to findings of a nation-
al survey on intra-laboratory TAT for some common 
routine and STAT laboratory analyses performed in 
479 laboratories in China which found the median 
within-laboratory TAT for stat and routine glucose 
to be 45 min and 130 min, respectively (24).
We applied a systematic outlier analysis to identify 
reasons for the high TAT in our laboratory by ana-
lysing the requests with the highest TATs (above 
the median within-laboratory TAT; 147 min). A CAP 
Q-Probes study applied a similar approach by ana-
lysing outlier TAT events to help determine the 
causes of delays in the TAT process for STAT tests 
from emergency departments and intensive care 
units. However, they used an arbitrarily chosen 
70-minute TAT to define outliers (25).
The breakdown of the TAT of CSF chemistry re-
quests in our laboratory identified transport of 
sample to the laboratory as the main culprit for 
high total TAT. A delayed transport of samples to 
the laboratory impacts negatively on the quality 
of laboratory results (26). The increasing need for 
laboratories to become more involved in pre-pre-
analytical issues has been emphasized (27). Fur-
thermore, the role of inappropriate sampling on 
CSF chemistry TAT in this study underscores the 
importance of sample collection and handling on 
the quality of laboratory output, as highlighted in 









I . Sample labelling
Work shift
Regular hours 24 2 26
0.012Evening hours 4 4 8
Night hours 17 9 26
II . Transportation to work area
Work Shift
Regular hours* 17 8 25
0.369Evening hours* 5 2 7
Night hours 22 4 26
Shared CSF 
sample
Shared sample* 0 3 3
0.001No shared 
sample *† 38 10 48
III . Analysis phase
Work shift
Regular hours* 19 6 25
1.000Evening hours* 5 2 7
Night hours 20 6 26
Repeat testing
Repeat testing* 19 6 25
1.000No repeat 
testing* 25 8 33
*one of the two missing data for time of receipt at work 
station which affected computing of TAT for transport to 
work area and Analysis phases (see Table 2).
† Seven requests missing record of number of tubes.
TAT – turnaround time.
P < 0.05 considered statistically significant.
Table 4. “Proposed reasons for long TAT” and the upper quar-
tile of TAT for “labelling”, “transportation to work area” and 
“analysis” phases
from the FGD. Amongst the 60 cases, repeat test-
ing in 34 cases (34 / 60) and shared CSF sample in 
only 4 (4 / 60) cases were observed. Equal num-
bers of cases (26 / 60) occurred during regular 
hours and the night shift (Table 4).
The work shift was significantly associated with 
the highest quartile of TAT for the labelling pro-
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Suggestions from interviews of laboratory staff 
identified the sharing of samples with the microbi-
ology laboratory as the main cause of high TAT for 
CSF chemistry. Findings from this study revealed 
that whilst this is a contributory factor, it account-
ed for at most 7% of the cases of high TAT and only 
impacted on the “transport to work area” phase of 
“sample processing”. This highlights the fact that 
changes in laboratory operations that are not evi-
dence-based may have little impact whilst damag-
ing root causes may be missed. This phase of labo-
ratory operation could be improved by educating 
clinicians on the need for appropriate sampling.
Our TAT for the reporting phase for CSF chemistry 
was within recommended 6 minutes suggested by 
Ricos et al. (29). We also found that efforts to fast-
track the pre-analytical handling of emergency 
samples like CSF are effective for the registration 
phase as evidenced by the shorter median dura-
tion of this period for CSF chemistry when com-
pared with plasma glucose. The sample process-
ing phase however, appears to have an identical 
TAT for both tests. We expected a considerably 
lower TAT for CSF chemistry, as this is a STAT test, 
when compared to a routine test such as plasma 
glucose. Our findings demonstrate that sample 
processing was responsible for most of the within-
laboratory TAT.
Our process-mapping investigation of the “sample 
processing” phase TAT indicated that samples 
were processed more slowly during evening and 
night work hours. This is contrary to a study from 
Pakistan which found that more delays in TAT of 
STAT tests occurred in the morning shift (30). The 
delays in TAT in relation to work schedule have 
been suggested to be due to an imbalance be-
tween workload and staffing (24,30). In our labora-
tory, this is particularly noticeable as it affects la-
belling of samples which is a time-consuming 
manual process. Therefore, the TAT for labelling is 
closely related to the number of staff available to 
perform the task. Although the sample through-
put is generally expected to be lower during even-
ing and night shifts, this period also coincides with 
the arrival of samples from remote peripheral hos-
pitals. Our findings suggest a review in workforce 
distribution is necessary. 
Although the analytical phase TAT was not signifi-
cantly affected by repeat testing for critical con-
centrations, the frequency of occurrence of repeat 
testing for CSF chemistry is a concern. Apart from 
the unnecessary consumption of reagents and ex-
tensive additional workload, the impact on TAT for 
an individual request may not be easily quantified. 
A previous study in our laboratory found that 
there was no significant difference between val-
ues obtained at initial testing and those from re-
peat testing for critical concentrations (31). 
A limitation of our study is that we were unable to 
objectively determine whether addressing the 
causes of high TAT identified in this study will re-
duce the TAT. This will require follow-up and re-au-
dit after instituting the suggested changes. Addi-
tionally, the number of cases in the regular, even-
ing and night shifts may have been disproportion-
al given the difference in duration of the shifts. A 
further limitation is that due to time constraints, 
only 60 cases with high TAT were analysed. Analy-
sis of a larger number may have revealed more 
causes of high TAT.  The reliability of our results 
may have been affected by the exclusion of over a 
quarter of our samples due to missing entries or 
errors. Entry at work station time was recorded 
manually by the technologists on the bench. Non-
conformities in entering this time point were re-
sponsible for some missing calculations. Also, the 
CSF chemistry TAT was not compared with TAT of 
other STAT tests.
Despite these limitations, our study has demon-
strated how systematic laboratory audits can be 
applied as a tool for root-cause analysis of prob-
lems in the clinical laboratory, particularly as it re-
lates to TAT. Our study provides evidence that can 
be used as a basis for making relevant changes to 
public laboratory services. The National Health 
Laboratory Service (NHLS) has established guide-
lines stating the acceptable TAT for all tests covered 
by their service. However, the NHLS did not specify 
TAT for analysis of CSF chemistry as a distinct sam-
ple, which could be useful considering the unique 
challenge of analysing of CSF chemistry as a panel. 
In conclusion, we found that careful and methodi-
cal examination of the critical “operational” steps 
involved in the total testing process will reveal the 
Biochemia Medica 2016;26(2):194–201  http://dx.doi.org/10.11613/BM.2016.021 
200
Imoh LC. et al. Laboratory audit and turnaround time improvement 
drivers of high TAT that may have been obscured 
in the traditional methods of assessing TAT by only 
reporting the total or within-laboratory TATs. We 
found that the TAT for CSF chemistry testing was 
unacceptably high, even though this is a suppos-
edly STAT test. Transport of the sample to the labo-
ratory was identified to be the main cause of delay 
followed by delays in sample processing during 
the evening and night shifts. Causes such as shar-
ing of sample and repeat testing were minor con-
tributors. The results of this audit will be used to 
change pre-analytical practices in our laboratory 
with the aim of improving TAT and customer satis-
faction.
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